First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 91
Strong growth among long-acting haemophilia B products
as Refixia®/RebinynⓇ is set for launch in the EU and the USA
Reported recombinant FIX sales
Benefix® AlprolixⓇ
IdelvionⓇ
RefixiaⓇ/RebinynⓇ launched in first countries
• Launched in the first EU countries in 2017
Sales
(USD million)
1,400
1,200
1,000
800
600
400
200
0
2011
CAGR: 10.1%¹
2017
•
Launched in the USA in February 2018
•
RefixiaⓇ/RebinynⓇ offers a unique clinical profile that brings
factor levels into the non-haemophilia range for adults and
adolescents
• Dialogue ongoing with the FDA and EMA to establish path
forward to obtain routine prophylaxis indication in the USA
and complete paediatric indication in Europe to include
children younger than 12 years old
1 CAGR for 6-year period
FIX: Coagulation factor IX
Source: Company reports (Does not include RixubisⓇ as sales are not reported separately).
changing
FDA: US Food and Drug Administration; EMA: European Medicines Agency
rFIX: Recombinant coagulation factor IX
diabetes®
novo nordiskView entire presentation